Clinical trials recruiting for HER2-positive breast cancer
75
Recruiting trials
38
US states with sites
36
Countries
3%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Trastuzumab | 13 |
| Pertuzumab | 8 |
| Docetaxel | 6 |
| Paclitaxel | 6 |
| Pyrotinib | 5 |
| Capecitabine | 4 |
| BL-M07D1 | 3 |
| Carboplatin | 3 |
| Neratinib | 3 |
| Trastuzumab deruxtecan | 3 |
| Zanidatamab | 3 |
| Cyclophosphamide | 2 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| New York | 9 |
| Florida | 8 |
| New Jersey | 6 |
| Texas | 6 |
| Colorado | 5 |
| Illinois | 5 |
| Massachusetts | 5 |
| Tennessee | 5 |
| California | 4 |
| Michigan | 4 |
| North Carolina | 4 |
| Virginia | 4 |
Top cities
Houston, Texas 6New York, New York 6Boston, Massachusetts 5Chicago, Illinois 5Dallas, Texas 4Nashville, Tennessee 4Tampa, Florida 4Aurora, Colorado 3Birmingham, Alabama 3Cleveland, Ohio 3
Self-screener
Recruiting trials
- A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
- A Phase 1/1b Study of IAM1363 in HER2 Cancers
- A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
- A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS)
- A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer
- A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy
- A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
- A Study of Surgery and Radiotherapy in People With Breast Cancer
- A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
- A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients
- A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
- Adjuvant Therapy Choice for Non-pCR HER2 Positive Early Breast Cancer After Neoadjuvant Therapy
- Adjuvant Therapy With Neratinib in HER2 Positive Early Breast Cancer
- Adjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined Target Therapy
- Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab
- Asian Multicenter Prospective Study in HER2 Positive Early Breast Cancer for Detecting MRD by ctDNA;HARMONY Study
- Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery
- BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer
- Basket Study for Oligo-metastatic Breast Cancer
- Chemotherapy Combined With Targeted Therapy for High-risk HER2 Positive and Lymph Node Negative Early Breast Cancer
- Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer
- Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC
- DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer
- Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer
- De-escalation of Neoadjuvant Chemotherapy Regimens With Targeted Therapy Among HER2 Positive Patients
- Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests.
- Diagnostic HER2DX-guided Treatment for Patients wIth Early-stage HER2-positive Breast Cancer
- Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)
- Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC
- Efficacy and Safety of Trastuzumab-rezetecan in HER2-Expressing Breast Cancer
- Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure
- Evaluation of the Cardioprotective Effect of Nebivolol on Trastuzumab-Induced Cardiotoxicity in Breast Cancer Patients
- Four Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among Low Risk HER2 Positive Patients
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
- HER-2 B Cell Peptide Vaccine
- HER2 Vaccine for Locally Advanced Breast Cancer
- HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer
- Identification of Genetic Determinants for Treatment Resistance/Sensitivity and/or Toxicity in Adjuvant Setting for HER2 Positive Breast Cancer
- Identification of Risk Factors for Brain Recurrence in Patients With HER2-positive Localised Breast Cancer
- Imaging Versus Cardiac Biomarker Monitored HER2 Directed Therapy in Patients With Breast Cancer
- Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer
- Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI
- Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05)
- Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer
- Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer
- PRE-ISPY Phase I/II Oncology Platform Program
- Pilot Study on the Clinical Efficacy of Focused Ultrasound-Mediated Targeted Drug Delivery System Combined With Neoadjuvant Therapy for HER2-Positive Breast Cancer
- Pre Operative Trastuzumab in Operable Breast Cancer
- Predicting BReast cAncer Response to neoadjuVant Therapy by ctDNA Assessment
- Probiotics for Prevention of Neratinib-Induced Diarrhea in Breast Cancer Patients
- Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer
- Pyrotinib Combined With Trastuzumab for Maintenance Therapy After First-line TH (P) Therapy for HER2+ABC
- Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer
- Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer
- Pyrotinib in Women With High-risk in Early Stage Breast Cancer
- RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study
- RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
- Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd
- Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
- Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
- Study of Screening Brain MRIs in Stage IV Breast Cancer
- TRUDI: TDXD+Durva in HER2+/Low IBC
- Taxane Combined Targeted Therapy for Low-risk HER2 Positive and Lymph Node Negative Breast Cancer
- The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).
- The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- The Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients.
- Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer
- Trastuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-Positive Early Breast Cancer
- Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
- Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer
- Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study
- Tumor-microenvironment Spatial Interaction to Identify Markers of Resistance to Therapy in HER2+ Breast Cancer Patients
- fREEDOM: REsonance for Early Detection Of Breast Cancer Metastases
Related conditions
Trials recruiting for HER2-positive breast cancer often also study these conditions. Each links to its own recruiting-trial list.
Breast cancer 2239Triple-negative breast cancer 138Metastatic breast cancer 131Early-stage Breast Cancer 27Hormone Receptor-Positive Breast Cancer 24HER2-negative Breast Cancer 57Triple-Negative Breast Cancer (TNBC) 35Lung cancer 2180Locally Advanced Breast Cancer 13HER2 Low Breast Cancer 7
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for HER2-positive breast cancer trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.